Close Menu

NEW YORK (GenomeWeb) — Natera announced today that it has partnered with the Fox Chase Cancer Center to evaluate the company's Signatera circulating tumor DNA (ctDNA) assay for monitoring kidney cancer recurrence.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.